Browse by Phase
Phase 1 / Phase 2 Clinical Trials
Phase 1/2 combined trials evaluate both safety (Phase 1) and preliminary efficacy (Phase 2) in a single study protocol, often used to accelerate early development.
Total Trials
401
Recruiting Now
401
Top Conditions in Phase 1 / Phase 2
Frequently Asked Questions — Phase 1 / Phase 2 Trials
What are combined Phase 1/2 clinical trials?
Phase 1/2 trials are adaptive designs that evaluate both safety (Phase 1 objectives) and preliminary efficacy (Phase 2 objectives) within a single trial protocol. They are commonly used in oncology and rare disease research to accelerate development timelines. Dose escalation occurs in the Phase 1 portion, followed by expansion cohorts at the selected dose in the Phase 2 portion.
Why do sponsors combine Phase 1 and Phase 2?
Combining phases reduces development time and cost, particularly for conditions with high unmet need. For rare diseases or cancer indications, finding sufficient eligible patients can be challenging—a combined design uses the same patient pool more efficiently. Regulatory agencies including the FDA encourage adaptive designs to accelerate evidence generation for serious conditions.
How do I find Phase 1/2 trials I can join?
Phase 1/2 trials listed on ClinicalMetric are sourced from ClinicalTrials.gov and filtered by recruitment status. Each listing shows enrollment status, conditions studied, sponsor, participating sites, and estimated enrollment. Because Phase 1/2 trials often have narrow eligibility criteria, carefully review the protocol and discuss potential participation with your treating physician.
Active Phase 1 / Phase 2 Studies
NCT05322850 Phase 1, Phase 2
Recruiting
Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Ce...
Condition
Acute Myeloid Leukemia
Enrollment
40 pts
Location
United States
Sponsor
University of Florida
NCT07591649 Phase 1, Phase 2
Recruiting
Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT
Condition
Relapsed Adult AML
Enrollment
18 pts
Location
United States
Sponsor
Masonic Cancer Center, Univers
NCT07612215 Phase 1, Phase 2
Recruiting
Elacestrant in Advanced Triple Positive Breast Cancer
Condition
ER Positive, HER2 Positive Breast Cancer
Enrollment
50 pts
Location
United States
Sponsor
NYU Langone Health
NCT04685226 Phase 1, Phase 2
Recruiting
A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
Condition
Solid Tumors
Enrollment
310 pts
Location
China
Sponsor
Beijing InnoCare Pharma Tech C
NCT07097935 Phase 1, Phase 2
Recruiting
Study of HS-10516 Combination Therapy in Patients With Advanced Renal Cell Carci...
Condition
Advanced Clear Cell Renal Cell Carcinoma
Enrollment
104 pts
Location
China
Sponsor
Jiangsu Hansoh Pharmaceutical
NCT07038096 Phase 1, Phase 2
Recruiting
ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Ca...
Condition
Small Cell Lung Cancer
Enrollment
350 pts
Location
China
Sponsor
Suzhou Zelgen Biopharmaceutica
NCT02343042 Phase 1, Phase 2
Recruiting
Selinexor and Backbone Treatments of Multiple Myeloma Patients
Condition
Multiple Myeloma
Enrollment
300 pts
Location
United States, Canada
Sponsor
Karyopharm Therapeutics Inc
NCT07500220 Phase 1, Phase 2
Recruiting
Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC
Condition
Advanced Hepatocellular Carcinoma (HCC)
Enrollment
30 pts
Location
China
Sponsor
Beijing Biotech
NCT07301866 Phase 1, Phase 2
Recruiting
A Study Testing an Improved Dose of UM171 to Help Make Cord Blood Transplants Mo...
Condition
Acute Leukemia, High Risk
Enrollment
7 pts
Location
Canada
Sponsor
Ciusss de L'Est de l'Île de Mo
NCT03707262 Phase 1, Phase 2
Recruiting
Study of Combined Kidney and Blood Stem Cell Transplant From a Brother or Sister...
Condition
Renal Transplant Rejection
Enrollment
15 pts
Location
United States
Sponsor
Jeffrey Veale, MD
NCT07205718 Phase 1, Phase 2
Recruiting
A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
Condition
Advanced or Metastatic Solid Tumors
Enrollment
273 pts
Location
United States
Sponsor
Takeda
NCT06308588 Phase 1, Phase 2
Recruiting
Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients Wi...
Condition
Philadelphia Chromosome-Positive
Enrollment
40 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
NCT05372354 Phase 1, Phase 2
Recruiting
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-98634...
Condition
Multiple Myeloma
Enrollment
260 pts
Location
United States, Canada, Norway
Sponsor
Bristol-Myers Squibb
NCT05734066 Phase 1, Phase 2
Recruiting
Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants Wit...
Condition
Refractory Ewing Sarcoma
Enrollment
60 pts
Location
United States, Canada
Sponsor
Jazz Pharmaceuticals
NCT07612280 Phase 1, Phase 2
Recruiting
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-...
Condition
Essential Thrombocythemia (ET)
Enrollment
30 pts
Location
Australia
Sponsor
Jubilant Therapeutics Inc.
NCT04998396 Phase 1, Phase 2
Recruiting
A Study of AAV9 Gene Therapy in Participants With Canavan Disease (CANaspire Cli...
Condition
Canavan Disease
Enrollment
26 pts
Location
United States
Sponsor
Aspa Therapeutics
NCT07129473 Phase 1, Phase 2
Recruiting
Hyperemesis Gravidarum Risk Reduction With Metformin
Condition
Hyperemesis Gravidarum
Enrollment
224 pts
Location
United States
Sponsor
University of Southern Califor
NCT07226986 Phase 1, Phase 2
Recruiting
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetrax...
Condition
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
Enrollment
123 pts
Location
United States, Australia, France
Sponsor
Novartis Pharmaceuticals
NCT06167681 Phase 1, Phase 2
Recruiting
The Safety, Tolerability and Efficacy of NouvNeu001 for Parkinson's Disease
Condition
Parkinson Disease
Enrollment
40 pts
Location
China
Sponsor
iRegene Therapeutics Co., Ltd.
NCT07439094 Phase 1, Phase 2
Recruiting
A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lu...
Condition
Advanced Solid Tumors
Enrollment
140 pts
Location
United States
Sponsor
Chong Kun Dang Pharmaceutical
NCT06863194 Phase 1, Phase 2
Recruiting
Probiotic Supplementation and Disease Progression in CKD: A Randomized Trial
Condition
Kidney Disease, Chronic
Enrollment
72 pts
Location
Egypt
Sponsor
Mansoura University
NCT06974812 Phase 1, Phase 2
Recruiting
IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid T...
Condition
Unresectable Locally Advanced or Metastatic Solid Tumors
Enrollment
250 pts
Location
China
Sponsor
Innovent Biologics (Suzhou) Co
NCT06765005 Phase 1, Phase 2
Recruiting
IB/IIa Study of MG-K10 in Adolescent Moderately Severe Patients
Condition
Atopic Dermatitis
Enrollment
24 pts
Location
China
Sponsor
Shanghai Mabgeek Biotech.Co.Lt
NCT07235202 Phase 1, Phase 2
Recruiting
A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or...
Condition
Pancreatic Ductal Adenocarcinoma (PDAC)
Enrollment
45 pts
Location
China
Sponsor
Shenzhen Majory Biotechnology
NCT04278131 Phase 1, Phase 2
Recruiting
BS01 in Patients With Retinitis Pigmentosa
Condition
Retinitis Pigmentosa
Enrollment
20 pts
Location
United States
Sponsor
Bionic Sight LLC
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology